CL2013001643A1 - Pharmaceutical composition comprising: 1) n - [(2s) -2,3-dihydroxypropyl] -3- (2-fluoro-4-iodoanilino) pyridin-4-carboxamide and 2a) 2-amino-n- [3- [ [3- (2-Chloro-5-methoxyanilin) quinoxalin-2-yl] sulfamoyl] phenyl] -2-methylpropanamide or 2b) 2-amino-8-ethyl-4-methyl-6- (1h-pyrazole-5- il) pyrido [2,3-d] pyrimidin-7-one; its use for the treatment of cancer; a kit - Google Patents
Pharmaceutical composition comprising: 1) n - [(2s) -2,3-dihydroxypropyl] -3- (2-fluoro-4-iodoanilino) pyridin-4-carboxamide and 2a) 2-amino-n- [3- [ [3- (2-Chloro-5-methoxyanilin) quinoxalin-2-yl] sulfamoyl] phenyl] -2-methylpropanamide or 2b) 2-amino-8-ethyl-4-methyl-6- (1h-pyrazole-5- il) pyrido [2,3-d] pyrimidin-7-one; its use for the treatment of cancer; a kitInfo
- Publication number
- CL2013001643A1 CL2013001643A1 CL2013001643A CL2013001643A CL2013001643A1 CL 2013001643 A1 CL2013001643 A1 CL 2013001643A1 CL 2013001643 A CL2013001643 A CL 2013001643A CL 2013001643 A CL2013001643 A CL 2013001643A CL 2013001643 A1 CL2013001643 A1 CL 2013001643A1
- Authority
- CL
- Chile
- Prior art keywords
- amino
- methoxyanilin
- iodoanilino
- methylpropanamide
- quinoxalin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42146510P | 2010-12-09 | 2010-12-09 | |
US201161436258P | 2011-01-26 | 2011-01-26 | |
US201161467485P | 2011-03-25 | 2011-03-25 | |
FR1159940 | 2011-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013001643A1 true CL2013001643A1 (en) | 2014-03-28 |
Family
ID=45464841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013001643A CL2013001643A1 (en) | 2010-12-09 | 2013-06-07 | Pharmaceutical composition comprising: 1) n - [(2s) -2,3-dihydroxypropyl] -3- (2-fluoro-4-iodoanilino) pyridin-4-carboxamide and 2a) 2-amino-n- [3- [ [3- (2-Chloro-5-methoxyanilin) quinoxalin-2-yl] sulfamoyl] phenyl] -2-methylpropanamide or 2b) 2-amino-8-ethyl-4-methyl-6- (1h-pyrazole-5- il) pyrido [2,3-d] pyrimidin-7-one; its use for the treatment of cancer; a kit |
Country Status (22)
Country | Link |
---|---|
US (1) | US20140024653A1 (en) |
EP (1) | EP2648729A1 (en) |
JP (1) | JP2013544892A (en) |
KR (1) | KR20140011311A (en) |
CN (1) | CN103402518A (en) |
AR (1) | AR084216A1 (en) |
AU (1) | AU2011338354A1 (en) |
BR (1) | BR112013014198A2 (en) |
CA (1) | CA2820748A1 (en) |
CL (1) | CL2013001643A1 (en) |
CR (1) | CR20130246A (en) |
DO (1) | DOP2013000131A (en) |
MA (1) | MA34815B1 (en) |
MX (1) | MX2013006319A (en) |
NZ (1) | NZ611581A (en) |
PE (1) | PE20140702A1 (en) |
RU (1) | RU2013131241A (en) |
SG (1) | SG190368A1 (en) |
TW (1) | TW201306837A (en) |
UY (1) | UY33790A (en) |
WO (1) | WO2012078832A1 (en) |
ZA (1) | ZA201303687B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013243429A1 (en) * | 2012-04-06 | 2014-10-23 | Merck Patent Gmbh | Methods for treating cancer using PI3K inhibitor and MEK inhibitor |
RU2684407C2 (en) * | 2012-10-11 | 2019-04-09 | Мерк Патент Гмбх | Combination of 6-oxo-1,6-dihydro-pyridazine derivative having anticolic activity, with mek inhibitor |
US9962385B2 (en) | 2014-02-07 | 2018-05-08 | Verastem, Inc. | Methods and compositions for treating abnormal cell growth |
WO2016014390A1 (en) * | 2014-07-25 | 2016-01-28 | Merck Patent Gmbh | Compositions and methods for mek inhibitor combination therapy in the treatment of cancer |
MA51309A (en) * | 2017-12-22 | 2021-03-31 | Adienne S A | QUANTITATIVE CELLULAR PROCESS FOR DETERMINING THE BIOLOGICAL ACTIVITY OF ANTI-CD26 LIGAND |
WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
BR112023006954A2 (en) * | 2020-10-16 | 2024-01-16 | Memorial Sloan Kettering Cancer Center | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
-
2011
- 2011-12-07 AR ARP110104595A patent/AR084216A1/en unknown
- 2011-12-08 BR BR112013014198A patent/BR112013014198A2/en not_active IP Right Cessation
- 2011-12-08 CN CN2011800671706A patent/CN103402518A/en active Pending
- 2011-12-08 PE PE2013001394A patent/PE20140702A1/en not_active Application Discontinuation
- 2011-12-08 SG SG2013039367A patent/SG190368A1/en unknown
- 2011-12-08 MX MX2013006319A patent/MX2013006319A/en not_active Application Discontinuation
- 2011-12-08 CA CA2820748A patent/CA2820748A1/en not_active Abandoned
- 2011-12-08 AU AU2011338354A patent/AU2011338354A1/en not_active Abandoned
- 2011-12-08 TW TW100145212A patent/TW201306837A/en unknown
- 2011-12-08 KR KR1020137017879A patent/KR20140011311A/en not_active Application Discontinuation
- 2011-12-08 RU RU2013131241/15A patent/RU2013131241A/en not_active Application Discontinuation
- 2011-12-08 NZ NZ611581A patent/NZ611581A/en not_active IP Right Cessation
- 2011-12-08 WO PCT/US2011/063871 patent/WO2012078832A1/en active Application Filing
- 2011-12-08 MA MA36091A patent/MA34815B1/en unknown
- 2011-12-08 JP JP2013543331A patent/JP2013544892A/en not_active Abandoned
- 2011-12-08 EP EP11806025.0A patent/EP2648729A1/en not_active Withdrawn
- 2011-12-09 UY UY0001033790A patent/UY33790A/en not_active Application Discontinuation
-
2013
- 2013-05-21 ZA ZA2013/03687A patent/ZA201303687B/en unknown
- 2013-05-27 CR CR20130246A patent/CR20130246A/en unknown
- 2013-06-07 CL CL2013001643A patent/CL2013001643A1/en unknown
- 2013-06-07 US US13/912,647 patent/US20140024653A1/en not_active Abandoned
- 2013-06-07 DO DO2013000131A patent/DOP2013000131A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR084216A1 (en) | 2013-05-02 |
CN103402518A (en) | 2013-11-20 |
RU2013131241A (en) | 2015-01-20 |
JP2013544892A (en) | 2013-12-19 |
MA34815B1 (en) | 2014-01-02 |
NZ611581A (en) | 2015-02-27 |
WO2012078832A1 (en) | 2012-06-14 |
PE20140702A1 (en) | 2014-06-26 |
MX2013006319A (en) | 2013-07-03 |
CA2820748A1 (en) | 2012-06-14 |
EP2648729A1 (en) | 2013-10-16 |
CR20130246A (en) | 2013-09-03 |
AU2011338354A1 (en) | 2013-06-27 |
UY33790A (en) | 2012-07-31 |
DOP2013000131A (en) | 2013-11-15 |
BR112013014198A2 (en) | 2016-09-13 |
US20140024653A1 (en) | 2014-01-23 |
ZA201303687B (en) | 2014-01-29 |
SG190368A1 (en) | 2013-06-28 |
KR20140011311A (en) | 2014-01-28 |
TW201306837A (en) | 2013-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013001643A1 (en) | Pharmaceutical composition comprising: 1) n - [(2s) -2,3-dihydroxypropyl] -3- (2-fluoro-4-iodoanilino) pyridin-4-carboxamide and 2a) 2-amino-n- [3- [ [3- (2-Chloro-5-methoxyanilin) quinoxalin-2-yl] sulfamoyl] phenyl] -2-methylpropanamide or 2b) 2-amino-8-ethyl-4-methyl-6- (1h-pyrazole-5- il) pyrido [2,3-d] pyrimidin-7-one; its use for the treatment of cancer; a kit | |
NI201200072A (en) | METHODS AND COMPOSITIONS TO TREAT CANCER | |
CL2014000492A1 (en) | Compounds derived from n- [3- (1,2,4-oxadiazol- (5-yl / amino / carbamoyl) phenyl] imidazo [1,2-a] pirdine-3-carboxamide, c-kit kinase inhibitors; pharmaceutical composition; and its use for the treatment of Alzheimer's disease, arthritis, atherosclerosis, among others | |
CL2012003026A1 (en) | Pharmaceutical composition comprising pioglitazone and linagliptin; preparation procedure; Use in the treatment of type 2 diabetes or obesity. | |
CL2013003372A1 (en) | Compounds derived from spiro- [1,3] -oxacins and spiro- [1,4] -oxacepins, inhibitors of bace1 and / or bace2; pharmaceutical composition; procedure to prepare them; and its use in the treatment and / or prophylaxis of Alzheimer's disease and diabetes. | |
CL2011002739A1 (en) | Compounds derived from 3- (1h-pyrrolo [2,3-b] pyridine-3-carbonyl) -benzenesulfonamide; pharmaceutical composition comprising them; kit; and their use as raf inhibitors for the treatment of a selected disease or condition of melanoma, glioma, glioblastoma multiforme, colorectal cancer, lung cancer, among others. | |
CL2009000349A1 (en) | Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease. | |
CO6501189A2 (en) | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
CL2007002207A1 (en) | COMPOUNDS DERIVED FROM SULFONYLAMINES; PHARMACEUTICAL COMPOSITION; AND USE OF COMPOUNDS IN THE TREATMENT OF GLAUCOMA. | |
CL2013001654A1 (en) | Compounds derived from 6-amino-2-phenylamino-1h-benzimidazol-5-carboxamide; pharmaceutical composition; and its use in the treatment and / or prevention of inflammatory diseases and / or associated conditions, in particular pain. | |
CL2013001947A1 (en) | Pharmaceutical composition comprising pioglitazone; use of pioglitazone to treat Alzheimer's; composition comprising pioglitazone. | |
CL2008001076A1 (en) | COMPOUNDS DERIVED FROM SULFONAMIDE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER. | |
BRPI0806531A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND. | |
BRPI0921699A2 (en) | antioxidant complex, cosmetic and pharmaceutical compositions containing said complex and use of this complex | |
CL2007000161A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER. | |
BRPI0922233A2 (en) | compounds, pharmaceutical compositions and methods for use in the treatment of metabolic syndromes. | |
CL2014002557A1 (en) | Bicyclic compounds of pyrazinone; preparation procedure; pharmaceutical composition; kit; and use in the treatment and / or prevention of cardiovascular diseases, cancer, among others. | |
BR112012020719A2 (en) | herbicidal formulation herbicidal plant treatment method method of increasing the effectiveness of a herbicidal formulation, and use of a composition | |
CL2007002920A1 (en) | COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS. | |
CL2014000849A1 (en) | Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases. | |
BRPI1009781A2 (en) | compounds for the treatment of metabolic disorders, pharmaceutical compositions comprising them and their use | |
CL2012003322A1 (en) | Compounds derived from substituted benzamide; pharmaceutical composition; and use in the treatment of cancer. | |
CL2008000110A1 (en) | USE OF COMPOUNDS DERIVED FROM PIRANONA SUBSTITUTED FOR THE TREATMENT OF METABOLIC SYNDROME; AND COMPOUNDS DERIVED FROM PIRANONA SUBSTITUTED. | |
CL2013002971A1 (en) | Compounds derived from 5- (phenyl / pyridinyl-ethynyl) -2-pyridine / 2-pyrimidine-carboxamide, mglur5 modulators; pharmaceutical composition comprising them; their preparation process; and its use in the treatment of schizophrenia or cognitive diseases. | |
BRPI0912687A2 (en) | use of probiotic bacteria for the treatment of hyperhomocysteinemia |